冠心病患者血清P-选择素水平与血脂、血糖相关性分析被引量：3

The Correlation Analysis Among P-selectin Levels,Serum Lipids and Blood Glucose in Patients With Coronary Heart Disease

下载PDF

导出

摘要目的探讨冠心病患者血清P-选择素水平与血脂、血糖相关性,评价P-选择素在冠心病预后估计中的意义。方法以42例体检健康者为对照组,42例冠心病患者作为观察组,观察组中包括不稳定型心绞痛患者22例(不稳定型心绞痛组),急性心梗患者20例(急性心梗组),三组患者都分别测定其P-选择素、空腹血糖(FBG)、果糖和血脂(TC、TG、LDL、HDL)含量水平。结果对照组P-选择素与血脂无明显相关性,观察组比对照组P-选择素含量明显升高(P<0.05),TC及LDL含量也明显升高(P<0.05),但是HDL含量明显减少(P<0.05)。观察组中两组比较,三项血脂指标相比较差异均无显著性(P>0.05)。观察组与对照组相比,血糖含量都比较接近,三者间差异均无显著性(P>0.05)。结论冠心病患者血清P-选择素与血脂含量存在良好的相关性,其中与TC、与LDL含量呈正相关性,与HDL呈负相关性,而与血糖含量的相关性不大。 Objective To investigate the correlation among P-selectin levels,serum lipids and blood glucose in patients with coronary heart disease,evaluate the significance of P-selectin in coronary heart disease prognosis.Methods 42 healthy persons as the control group（B group） ,42 cases of coronary heart disease as the observation group in which 22 cases of acute myocardial infarction were A1 group,20 cases of acute myocardial infarction were A2 group.The serum P-selectin,fasting glucose,fructose,lipids series（including TC,TG,LDL,HDL） were determined in all the cases.Results The P-selectin had no significant correlation with lipid in the B group.Compared with the B group,the P-selectin and blood lipids were significantly higher in A group（P〈0.05） .There was no significant difference in blood glucose（P〉0.05） for three groups.Conclusion The coronary heart disease patients with P-selectin and lipid levels can interact to increase atherosclerosis,increase platelet activation,but has little relation with the blood glucose level.

作者刘扬李招兵

机构地区南华大学附属南华医院心内科

出处《中南医学科学杂志》 CAS 2011年第4期441-443,共3页 Medical Science Journal of Central South China

关键词冠心病 P-选择素血糖血脂 coronary heart disease P-selectin glucose lipid

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献11

1屈晓冰,孙振球,陈美娟,陈珑珑.冠心病患者P-选择素水平及其与冠状动脉病变程度间的关系[J].中华流行病学杂志,2005,26(8):617-621. 被引量：33
2崔建和,李红,鲍艳梅,杨士军,张曼云,刘满庆.糖尿病患者血浆P-选择素的表达与临床意义[J].实用糖尿病杂志,2005,13(1):28-29. 被引量：1
3Bleske BE,Nicklas M,Bard RL,et al.Neutral effect on markers of heart failure,inflammation,endothelial activa-tion and function,and vagaltone after high-dose G-COR reductase inhibition in non-diabeticpatients with nonisch-emic cardiomyopathy and average low-density lipoprotein level. Journal of the American College of Cardiology . 2006
4Bruni F.Different effect of statins on platelet oxidized-LDL receptor(CD36and LOX-1)expression in hypercholesterolemic subjects. Clinical and Applied Thrombosis . 2005
5Mitsios JV,Papathanasiou AP,Rodis FI,et al.Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation . 2004
6Phillips,Barringhaus KG,Sanders JM, et al.Single Injection of P-Selectin or P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Blocks Neointima Formation After Arterial Injury in Apolipoprotein E-Deficient Mice. Circulation . 2003
7Chou CA,Wu CJ,Yang CH,et al.Levels and value of soluble P-selectin following acute myocardial infarction:evaluating the link between soluble P-selectin levels and recruitment of circulating white blood cells and the marker for the rapid diagnosis of chest pain. Chang Gund Med . 2005
8Laucella SA,Riarte A,Prado N,et al.Alpha 4 Integrins and siglyl Lewis x modulation in chronic Chagas disease:further evidence of persistent immune activation. Scandinavian Journal of Immunology . 2001
9Wu CC,Wang TW,Wang WY, et al.2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets. European Journal of Pharmacology . 2005
10Kalyanasundaram A,Elmore JR,Manazer JR,Golden A,Franklin DP,Galt SW,Zakhary EM,Carey DJ.Simvastatin suppresses experimental aortic aneurysm expansion. Journal of Vascular Surgery . 2006

二级参考文献17

1Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies : Part I. Circulation, 2003,108 : 1664-1672.
2Shebuski R J, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther, 2002,300 : 729-735.
3Carter AM, Anagnostopoulou K, Mansfield MW, et al. Soluble P-selectin levels, P-selectin polyrnorphisms and cardiovascular disease. J Thromb Haemost,2003,1 : 1718-1723.
4Braunwald E, Antman EM, Beasley JW, et ah ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2000, 36:970-1062.
5Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983,51 : 606.
6Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( committee to revise the 1993 guidelines for percutaneous translurninal coronary angioplasty ). J Am Coll Cardiol,2001,37 : 2215-2239.
7Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest, 1997, 99 :1037-1040.
8Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advance atherosclerosis in apoE-deficient mice.Circulation, 2000,101:2290-2295.
9Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand 1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient Mice. Circulation,2003,107 : 2244-2249.
10Hajicooi M, Sanati A, Ahmadieh A, et al. Circulating ICAM-1,VCAM-1 ,E-selectin,P-selectin and TNFalphaR Ⅱ in patients with coronary artery disease. Immunol Invest, 2003,32 : 245-257.